Blueweave
Monoclonal Antibody Therapeutics Market

Monoclonal Antibody Therapeutics Market

Monoclonal Antibody (mAb) Therapeutics Market, By Source (Human, Humanized, Chimeric, Murine); By Application/Therapy Area (Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, Cardiovascular Diseases, Others); By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Global Trend Analysis, Competitive Landscape & Forecast, 2019–2031

  • Published Date: February 2025
  • Report ID: BWC25080
  • Available Format: PDF
  • Page: 512

Report Overview

Increasing prevalence of chronic diseases, rising R&D investments, and expanding applications of mAbs are expected to boost the growth of Global Monoclonal Antibody (mAb) Therapeutics Market during the forecast period between 2025 and 2031.

Global Monoclonal Antibody (mAb) Therapeutics Market - Industry Trends & Forecast Report, 2031

Global Monoclonal Antibody (mAb) Therapeutics Market size was estimated to be worth USD 273.2 billion in 2024. During the forecast period between 2025 and 2031, Global Monoclonal Antibody (mAb) Therapeutics Market size is projected to grow at a robust CAGR of 11.2% reaching a value of USD 559.3 billion by 2031. Major growth factors for Global Monoclonal Antibody (mAb) Therapeutics Market include the rising prevalence of chronic diseases such as cancer and cardiovascular conditions, which are increasing the demand for biologics, as well as the growing use of mAb therapies in targeted treatments. Additionally, heightened awareness among patients and physicians about the effectiveness of mAb therapies is expected to further boost market expansion. Monoclonal antibodies, produced through cell lines or clones derived from immunized animals, play a crucial role in medical advancements, with their ability to target specific disease markers and pathogens contributing to their widespread use. The development of mAbs for COVID-19 treatment, including the FDA’s emergency use authorization of Eli Lilly’s bebtelovimab, has further accelerated market growth. The advantages of mAb therapies—such as specificity, effectiveness, and ease of delivery—have led to numerous product launches and approvals, with more than 100 mAb products receiving FDA approval. Innovations in antibody fragments, bispecific antibodies, and other advanced treatments are expected to expand therapeutic applications, while strategic initiatives by key market players continue to drive further growth.

Monoclonal Antibody Therapeutics Market

Monoclonal Antibody (mAb) Therapeutics – Overview

Monoclonal Antibody (mAb) Therapeutics refers to a class of biologic drugs made from identical immune cells that are clones of a single parent cell. These antibodies are designed to target specific antigens, such as disease markers or pathogens, and can be used for a wide range of therapeutic applications, including the treatment of cancers, autoimmune diseases, infectious diseases, and cardiovascular conditions. mAbs are produced through cell lines derived from immunized animals and have gained significant attention due to their high specificity, effectiveness, and ability to provide targeted treatment with minimal side effects.

Global Monoclonal Antibody (mAb) Therapeutics Market

Growth Drivers

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, including cancer, rheumatoid arthritis, and hepatitis B, is significantly driving Global Monoclonal Antibody (mAb) Therapeutics Market. These targeted therapies enhance immune responses by recognizing specific proteins on cells, offering effective treatment solutions. Over the past three decades, more than 100 monoclonal antibody therapies have been approved, revolutionizing disease management and improving patient outcomes. Additionally, the rise in infectious diseases such as COVID-19, Ebola, and HIV has expanded the scope of mAbs, demonstrating their critical role in modern medicine. Innovations like VIR-3434, which shows promise in treating chronic hepatitis B and D, further highlight the growing applications of mAbs. However, market accessibility remains a challenge, with high-income countries dominating adoption while affordability limits access in low- and middle-income regions. Addressing regulatory hurdles, investing in R&D, and enhancing production efficiency will be vital in ensuring equitable global access, driving sustained market growth and improving healthcare outcomes worldwide.

Challenges

High Cost of mAb Therapies

The high cost of monoclonal antibody (mAb) therapies is a significant barrier to market expansion, limiting accessibility and affordability for patients worldwide. Producing mAbs involves complex biotechnological processes, including cell culture, purification, and stringent quality control measures, which drive up manufacturing costs. On average, mAb therapies cost between USD 15,000 and USD 200,000 per patient per year, making them unaffordable for many, especially in low- and middle-income countries. Additionally, these high costs place a financial burden on healthcare systems and insurance providers, restricting widespread adoption. Despite the growing demand for targeted biologic treatments in oncology, autoimmune disorders, and infectious diseases, the prohibitive pricing curtails patient access and slows market penetration. Efforts to reduce costs, such as biosimilar development and innovative manufacturing techniques, aim to address this challenge. However, until pricing barriers are significantly lowered, Global mAbs Therapeutics Market will continue to face growth constraints.

Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

Escalating geopolitical tensions could present both opportunities and challenges for Global Monoclonal Antibody (mAb) Therapeutics Market. Trade restrictions, supply chain disruptions, and regulatory uncertainties may hinder the production and distribution of mAbs, increasing costs and limiting patient access. Additionally, geopolitical instability could affect pharmaceutical collaborations and investment in biologic drug development. However, heightened government focus on healthcare security and domestic biopharmaceutical manufacturing could drive regional production capabilities and reduce dependence on imports. While geopolitical uncertainties create barriers, they also encourage innovation in supply chain resilience and alternative manufacturing strategies, shaping the future growth of the mAb therapeutics market.

Global Monoclonal Antibody (mAb) Therapeutics Market

Segmental Coverage

Global Monoclonal Antibody (mAb) Therapeutics Market – By Source

Based on source, Global Monoclonal Antibody (mAb) Therapeutics Market is divided into Human, Humanized, Chimeric, and Murine segments. The human segment holds the highest share in Global Monoclonal Antibody (mAb) Therapeutics Market by source. Human-derived mAbs are widely used in tumor immunotherapy, medical imaging, and neutralizing toxins, viruses, and drug overdoses due to their superior efficacy and safety. Unlike mouse-derived mAbs, which may trigger immune responses, human-origin mAbs exhibit lower immunogenicity and efficiently modulate effector functions. Advanced techniques like phage display and hybridoma technology in transgenic mice enable their production. With continuous advancements in genetic engineering, the development and adoption of fully human mAbs are expected to rise, further enhancing therapeutic interventions and patient outcomes.

Monoclonal Antibody Therapeutics Market Size

Global Monoclonal Antibody (mAb) Therapeutics Market – By Application/Therapeutic Area

Global Monoclonal Antibody (mAb) Therapeutics Market by application/therapeutic area is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, Cardiovascular Diseases, and other therapeutic areas. The oncology segment holds the highest share in Global Monoclonal Antibody (mAb) Therapeutics Market by application/therapeutic area, driven by the increasing number of regulatory approvals for mAbs targeting various types of cancer. The rising incidence of cancer is a key factor fueling this growth, as mAbs offer fewer side effects compared to other drugs and chemotherapy. Current mAb treatments target cancers such as non-small cell lung cancer, brain tumors, ovarian, breast, gastric, melanoma, colorectal cancer, and Hodgkin’s lymphoma. Additionally, the use of mAbs for autoimmune diseases, particularly rheumatoid arthritis, is expected to grow rapidly due to the rising prevalence of these conditions and the identification of cytokine proteins involved in inflammatory pathways that can be targeted for disease mitigation. mAbs are designed to bind to specific proteins on cancer cells, either killing them or inhibiting their growth. With a broad range of mAb therapies available, some target specific cancers and others effective across multiple types, their effectiveness and versatility in oncology are driving advancements and growth in cancer treatment strategies.Bottom of Form

Monoclonal Antibody Therapeutics Market Share

Global Monoclonal Antibody (mAb) Therapeutics Market – By Distribution Channel

On the basis of distribution channel, Global Monoclonal Antibody (mAb) Therapeutics Market is segmented into Hospitals, Retail Pharmacies, and Online Pharmacies segments.

Global Monoclonal Antibody (mAb) Therapeutics Market – By Region

The in-depth research report on Global Monoclonal Antibody (mAb) Therapeutics Market covers a number of country-specific markets across five major regions: North America, Europe, Asia Pacific (APAC), Latin America (LATAM), and Middle East and Africa (MEA). North America region dominates Global Monoclonal Antibody (mAb) Therapeutics Market, driven by substantial healthcare expenditures, particularly in United States, where spending significantly surpasses that of other countries, although it does not always lead to better healthcare outcomes. High service prices and utilization rates contribute to the rising costs in United States. Meanwhile, Canada’s medical sector is thriving, supported by innovative research, technological advancements, and growing demand for healthcare services. This dynamic evolution in Canada’s healthcare system further strengthens the region's position and growth potential in the monoclonal antibody therapeutics market. In January 2022, GSK and Vir Biotechnology secured an agreement with the United States government to purchase additional supplies of sotrovimab, which has been authorized for early COVID-19 treatment.

Monoclonal Antibody Therapeutics Market Growth

Competitive Landscape

Global Monoclonal Antibody (mAb) Therapeutics Market is highly competitive, as a number of companies are competing to gain a significant market share. Key players in the market include F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, and Thermo Fisher Scientific Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In February 2024 - AbbVie and OSE Immunotherapeutics formed a collaboration to advance the development of a new monoclonal antibody (mAb) aimed at addressing chronic inflammation.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2024

Base Year – 2024

Estimated Year – 2025

Forecast Period – 2025–2031

Facts Covered

Revenue in USD Billion

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Product/ Service Segmentation

Source, Application, Distribution Channel, Region

Key Players

F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, Thermo Fisher Scientific Inc

 

By Source

  • Human

  • Humanized

  • Chimeric

  • Murine

By Application/Therapy Area

  • Oncology

  • Autoimmune Diseases

  • Infectious Diseases

  • Hematological Disorders

  • Cardiovascular Diseases

  • Others

By Distribution Channel

  • Hospitals

  • Retail Pharmacies

  • Online Pharmacies

By Region

  • North America

  • Europe

  • Asia Pacific (APAC)

  • Latin America (LATAM)

  • Middle East and Africa (MEA)

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3. Global Monoclonal Antibody (mAb) Therapeutics Market Insights
    1. End User Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Increasing Prevalence of Chronic Diseases
        2. Growing Investments in (mAb) R&D Programs
        3. Expanding Applications
      2. Restraints
        1. High Cost of (mAb) Therapies
        2. Stringent Regulatory Requirements
      3. Opportunities
        1. Developing Novel (mAb) Therapies
        2. Growing Adoption of Personalized Medicines
      4. Challenges
        1. Competitions from Biosimilars
        2. Potential Side Effects
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Monoclonal Antibody (mAb) Therapeutics Market: Marketing Strategies
  5. Global Monoclonal Antibody (mAb) Therapeutics Market: Pricing Analysis
  6. Global Monoclonal Antibody (mAb) Therapeutics Market: Geography Analysis
    1. Global Monoclonal Antibody (mAb) Therapeutics Market, Geographical Analysis, 2024
    2. Global Monoclonal Antibody (mAb) Therapeutics, Market Attractiveness Analysis, 2024–2031
  7. Global Monoclonal Antibody (mAb) Therapeutics Market Overview
    1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Source
        1. Human
        2. Humanized
        3. Chimeric
        4. Murine
      2. By Application/Therapy Area
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Hematological Disorders
        5. Cardiovascular Diseases
        6. Others
      3. By Distribution Channel
        1. Hospitals
        2. Retail Pharmacies
        3. Online Pharmacies
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  8. North America Monoclonal Antibody (mAb) Therapeutics Market
    1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Source
      2. By Application
      3. By Distribution Channel
      4. By Country
        1. United States
          1. By Source
          2. By Application
          3. By Distribution Channel
        2. Canada
          1. By Source
          2. By Application
          3. By Distribution Channel
  9. Europe Monoclonal Antibody (mAb) Therapeutics Market
    1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Source
      2. By Application
      3. By Distribution Channel
      4. By Country
        1. Germany
          1. By Source
          2. By Application
          3. By Distribution Channel
        2. United Kingdom
          1. By Source
          2. By Application
          3. By Distribution Channel
        3. Italy
          1. By Source
          2. By Application
          3. By Distribution Channel
        4. France
          1. By Source
          2. By Application
          3. By Distribution Channel
        5. Spain
          1. By Source
          2. By Application
          3. By Distribution Channel
        6. Belgium
          1. By Source
          2. By Application
          3. By Distribution Channel
        7. Russia
          1. By Source
          2. By Application
          3. By Distribution Channel
        8. The Netherlands
          1. By Source
          2. By Application
          3. By Distribution Channel
        9. Rest of Europe
          1. By Source 
          2. By Application
          3. By Distribution Channel
  10. Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market
    1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Source
      2. By Application
      3. By Distribution Channel
      4. By Country
        1. China
          1. By Source
          2. By Application
          3. By Distribution Channel
        2. India
          1. By Source
          2. By Application
          3. By Distribution Channel
        3. Japan
          1. By Source
          2. By Application
          3. By Distribution Channel
        4. South Korea
          1. By Source
          2. By Application
          3. By Distribution Channel
        5. Australia and New Zealand
          1. By Source
          2. By Application
          3. By Distribution Channel
        6. Indonesia
          1. By Source
          2. By Application
          3. By Distribution Channel
        7. Malaysia
          1. By Source
          2. By Application
          3. By Distribution Channel
        8. Singapore
          1. By Source
          2. By Application
          3. By Distribution Channel
        9. Vietnam
          1. By Source
          2. By Application
          3. By Distribution Channel
        10. Rest of APAC
          1. By Source
          2. By Application
          3. By Distribution Channel
  11. Latin America Monoclonal Antibody (mAb) Therapeutics Market
    1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Source
      2. By Application
      3. By Distribution Channel
      4. By Country
        1. Brazil
          1. By Source
          2. By Application
          3. By Distribution Channel
        2. Mexico
          1. By Source
          2. By Application
          3. By Distribution Channel
        3. Argentina
          1. By Source
          2. By Application
          3. By Distribution Channel
        4. Peru
          1. By Source
          2. By Application
          3. By Distribution Channel
        5. Rest of LATAM
          1. By Source
          2. By Application
          3. By Distribution Channel
  12. Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market
    1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Source
      2. By Application
      3. By Distribution Channel
      4. By Country
        1. Saudi Arabia
          1. By Source
          2. By Application
          3. By Distribution Channel
        2. UAE
          1. By Source
          2. By Application
          3. By Distribution Channel
        3. Qatar
          1. By Source
          2. By Application
          3. By Distribution Channel
        4. Kuwait
          1. By Source
          2. By Application
          3. By Distribution Channel
        5. South Africa
          1. By Source
          2. By Application
          3. By Distribution Channel
        6. Nigeria
          1. By Source
          2. By Application
          3. By Distribution Channel
        7. Algeria
          1. By Source
          2. By Application
          3. By Distribution Channel
        8. Rest of MEA
          1. By Source
          2. By Application
          3. By Distribution Channel
  13. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Monoclonal Antibody (mAb) Therapeutics Company Market Share Analysis, 2024
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
  14. Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market
  15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. F. Hoffmann-La Roche Ltd
    2. Novartis AG
    3. Johnson & Johnson Services, Inc.
    4. GlaxoSmithKline plc
    5. Merck & Co., Inc.
    6. Amgen Inc
    7. Bristol Myers Squibb Company (US)
    8. Merck & Co Inc
    9. AstraZeneca plc
    10. Sanofi
    11. Bayer AG
    12. Eli Lilly and Company
    13. Thermo Fisher Scientific Inc
    14. Other Prominent Players
  16. Key Strategic Recommendations
  17. Research Methodology
    1.       Qualitative Research
      1.   Primary & Secondary Research
    2.       Quantitative Research
    3.       Market Breakdown & Data Triangulation
      1.   Secondary Research
      2.   Primary Research
    4.       Breakdown of Primary Research Respondents, By Region
    5.       Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

 

Figure 1       Global Monoclonal Antibody (mAb) Therapeutics Segmentation

Figure 2       Global Monoclonal Antibody (mAb) Therapeutics Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2024

Figure 4       Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 5       Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 6       Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 7       Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 8       Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Region, By Value (USD Billion), 2019–2031

Figure 9       North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 10     North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 11     North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 12     North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 13     North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031

Figure 14     United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 15     United States Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 16     United States Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 17     United States Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 18     Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 19     Canada Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 20     Canada Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 21     Canada Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 22     Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 23     Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 24     Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 25     Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 26     Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031

Figure 27     Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 28     Germany Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 29     Germany Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 30     Germany Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 31     United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 32     United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 33     United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 34     United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 35     Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 36     Italy Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 37     Italy Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 38     Italy Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 39     France Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 40     France Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 41     France Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 42     France Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 43     Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 44     Spain Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 45     Spain Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 46     Spain Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 47     Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 48     Belgium Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 49     Belgium Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 50     Belgium Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 51     Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 52     Russia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 53     Russia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 54     Russia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 55     The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 56     The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 57     The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 58     The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 59     Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 60     Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 61     Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 62     Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 63     Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 64     Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 65     Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 66     Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 67     Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031

Figure 68     China Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 69     China Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 70     China Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 71     China Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 72     India Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 73     India Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 74     India Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 75     India Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 76     Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 77     Japan Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 78     Japan Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 79     Japan Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 80     South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 81     South Korea Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 82     South Korea Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 83     South Korea Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 84     Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 85     Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 86     Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 87     Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 88     Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 89     Indonesia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 90     Indonesia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 91     Indonesia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 92     Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 93     Malaysia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 94     Malaysia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 95     Malaysia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 96     Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 97     Singapore Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 98     Singapore Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 99     Singapore Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 100   Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 101   Vietnam Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 102   Vietnam Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 103   Vietnam Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 104   Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 105   Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 106   Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 107   Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 108   Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 109   Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 110   Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 111   Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 112   Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031

Figure 113   Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 114   Brazil Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 115   Brazil Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 116   Brazil Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 117   Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 118   Mexico Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 119   Mexico Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 120   Mexico Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 121   Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 122   Argentina Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 123   Argentina Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 124   Argentina Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 125   Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 126   Peru Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 127   Peru Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 128   Peru Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 129   Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 130   Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 131   Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 132   Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 133   Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 134   Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 135   Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 136   Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 137   Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031

Figure 138   Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 139   Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 140   Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 141   Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 142   UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 143   UAE Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 144   UAE Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 145   UAE Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 146   Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 147   Qatar Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 148   Qatar Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 149   Qatar Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 150   Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 151   Kuwait Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 152   Kuwait Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 153   Kuwait Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 154   South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 155   South Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 156   South Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 157   South Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 158   Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 159   Nigeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 160   Nigeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 161   Nigeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 162   Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 163   Algeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 164   Algeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 165   Algeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

Figure 166   Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Figure 167   Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031

Figure 168   Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031

Figure 169   Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031

 

List of Tables

 

Table 1        Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 2        Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 3        Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 4        Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 5        Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Region, By Value (USD Billion), 2019–2031

Table 6        North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Table 7        North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031    

Table 8        North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031     

Table 9        North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031 

Table 10      North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031    

Table 11      United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 12      United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 13      United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 14      United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 15      Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 16      Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 17      Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 18      Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 19      Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 20      Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 21      Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 22      Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 23      Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031

Table 24      Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 25      Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 26      Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 27      Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 28      United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Table 29      United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031    

Table 30      United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031     

Table 31      United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031 

Table 32      Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 33      Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 34      Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 35      Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031    

Table 36      France Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 37      France Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 38      France Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 39      France Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 40      Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 41      Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 42      Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 43      Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 44      Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 45      Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 46      Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 47      Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 48      Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 49      Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 50      Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 51      Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 52      The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Table 53      The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031    

Table 54      The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031     

Table 55      The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031 

Table 56      Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Table 57      Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031    

Table 58      Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031     

Table 59      Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031 

Table 60      Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 61      Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 62      Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 63      Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 64      Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031

Table 65      China Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 66      China Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 67      China Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 68      China Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 69      India Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 70      India Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 71      India Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 72      India Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 73      Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 74      Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 75      Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 76      Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 77      South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 78      South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 79      South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 80      South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 81      Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031    

Table 82      Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031      

Table 83      Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 84      Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031      

Table 85      Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 86      Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 87      Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 88      Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 89      Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 90      Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 91      Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 92      Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 93      Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 94      Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 95      Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 96      Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 97      Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 98      Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 99      Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 100    Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 101    Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 102    Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 103    Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 104    Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 105    Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 106    Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 107    Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 108    Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 109    Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031    

Table 110    Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 111    Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 112    Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 113    Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 114    Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 115    Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 116    Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 117    Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 118    Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 119    Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 120    Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 121    Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 122    Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 123    Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 124    Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 125    Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031    

Table 126    Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 127    Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031    

Table 128    Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031     

Table 129    Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031 

Table 130    Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031

Table 131    Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031  

Table 132    Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031     

Table 133    Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031 

Table 134    Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031

Table 135    Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 136    Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 137    Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 138    Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 139    UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 140    UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 141    UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 142    UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031    

Table 143    Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031 

Table 144    Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 145    Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 146    Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 147    Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 148    Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 149    Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 150    Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 151    South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 152    South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 153    South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 154    South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 155    Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 156    Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 157    Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 158    Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 159    Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 160    Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 161    Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031

Table 162    Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 163    Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031        

Table 164    Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031

Table 165    Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031    

Table 166    Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031

Table 167    F. Hoffmann-La Roche Ltd Company Overview

Table 168    F. Hoffmann-La Roche Ltd Financial Overview

Table 169    Novartis AG Company Overview

Table 170    Novartis AG Financial Overview

Table 171    Johnson & Johnson Services, Inc. Company Overview

Table 172    Johnson & Johnson Services, Inc. Financial Overview

Table 173    GlaxoSmithKline plc Company Overview

Table 174    GlaxoSmithKline plc Financial Overview

Table 175    Merck & Co., Inc. Company Overview

Table 176    Merck & Co., Inc. Financial Overview

Table 177    Amgen Inc Company Overview

Table 178    Amgen Inc Financial Overview

Table 179    Bristol Myers Squibb Company (US) Company Overview

Table 180    Bristol Myers Squibb Company (US) Financial Overview

Table 181    Merck & Co Inc Company Overview

Table 182    Merck & Co Inc Financial Overview

Table 183    AstraZeneca plc Company Overview

Table 184    AstraZeneca plc Financial Overview

Table 185    Sanofi Company Overview

Table 186    Sanofi Financial Overview

Table 187    Bayer AG Company Overview

Table 188    Bayer AG Financial Overview

Table 189    Eli Lilly and Company: Company Overview

Table 190    Eli Lilly and Company Financial Overview

Table 191    Thermo Fisher Scientific Inc Company Overview

Table 192    Thermo Fisher Scientific Inc Financial Overview
 

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Monoclonal Antibody (mAb) Therapeutics Market size was estimated at USD 273.20 billion in 2024.
Ans: During the forecast period between 2025 and 2031, Global Monoclonal Antibody (mAb) Therapeutics Market size is expected to grow at a CAGR of 11.2% reaching a value of USD 559.3 billion by 2031.
Ans: Major factors driving the growth of Global Monoclonal Antibody (mAb) Therapeutics Market include an increasing prevalence of chronic diseases, rising R&D investments, and expanding applications.
Ans: Key players in Global Monoclonal Antibody (mAb) Therapeutics Market include F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, and Thermo Fisher Scientific Inc.
Ans: The human segment holds the largest market share of Global Monoclonal Antibody (mAb) Therapeutics Market by source.
Ans: North America is expected to grow at the fastest CAGR in Global Monoclonal Antibody (mAb) Therapeutics Market during the forecast period between 2025 and 2031.
array(1) {
  ["__ci_last_regenerate"]=>
  int(1739684662)
}